A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France

Published on May 1, 2014in PharmacoEconomics3.71
· DOI :10.1007/s40273-014-0144-z
Michael Drummond72
Estimated H-index: 72
(Ebor: University of York),
Gérard de Pouvourville21
Estimated H-index: 21
(ESSEC Business School)
+ 3 AuthorsHélène Cawston1
Estimated H-index: 1
Objectives Within Europe, contrasting approaches have emerged for rewarding the value added by new drugs. In Ireland, The Netherlands, Sweden and the UK, the price of, and access to, a new drug has to be justified by the health gain it delivers compared with current therapy, typically expressed in quality-adjusted life-years (QALYs) gained. By contrast, in France and Germany, the assessment of added benefit is expressed on an ordinal scale, based on an assessment of the clinical outcomes as compared with existing care. This assessment then influences price negotiations. The objective of this paper is to assess the pros and cons of each approach, both in terms of the assessments they produce and the efficiency and practical feasibility of the process.
  • References (14)
  • Citations (16)
10 Citations
8 CitationsSource
#1Koonal ShahH-Index: 15
#2Richard Cookson (Ebor: University of York)H-Index: 30
Last.Peter LittlejohnsH-Index: 33
view all 4 authors...
28 CitationsSource
#1Mw Bending (Ebor: University of York)H-Index: 6
#2John Hutton (Ebor: University of York)H-Index: 29
Last.C. McGrath (Pfizer)H-Index: 5
view all 3 authors...
11 CitationsSource
55 CitationsSource
#1Anne MasonH-Index: 22
#2Michael Drummond (Ebor: University of York)H-Index: 72
Last.Dennis W. RaischH-Index: 36
view all 5 authors...
71 CitationsSource
#1Fiona Clement (U of C: University of Calgary)H-Index: 25
#2Anthony HarrisH-Index: 43
Last.Braden J. Manns (U of C: University of Calgary)H-Index: 70
view all 6 authors...
243 CitationsSource
#1Marco Barbieri (UPF: Pompeu Fabra University)H-Index: 13
#2Neil Hawkins (Ebor: University of York)H-Index: 27
Last.Mark Sculpher (Ebor: University of York)H-Index: 75
view all 3 authors...
28 CitationsSource
35 Citations
#1Michael Drummond (Ebor: University of York)H-Index: 72
#2J. Sanford Schwartz (UPenn: University of Pennsylvania)H-Index: 61
Last.Sean D. Sullivan (UW: University of Washington)H-Index: 65
view all 7 authors...
257 CitationsSource
Cited By16
#1S. Cannizzo (Sant'Anna School of Advanced Studies)H-Index: 2
#2Valentina Lorenzoni (Sant'Anna School of Advanced Studies)H-Index: 15
Last.Giuseppe Turchetti (Sant'Anna School of Advanced Studies)H-Index: 18
view all 7 authors...
2 CitationsSource
#1Zdenko Tomić (University of Novi Sad)H-Index: 7
#2Ana Tomas (University of Novi Sad)H-Index: 3
Last.Ana Sabo (University of Novi Sad)H-Index: 10
view all 8 authors...
#1Aleksandra Torbica (Bocconi University)H-Index: 16
#2Rosanna Tarricone (Bocconi University)H-Index: 20
Last.Michael Drummond (Ebor: University of York)H-Index: 72
view all 3 authors...
6 CitationsSource
#1Kathryn M Antioch (Monash University)H-Index: 4
#2Michael Drummond (Ebor: University of York)H-Index: 72
Last.Hindrik VondelingH-Index: 14
view all 4 authors...
7 CitationsSource
#1Elena Nicod (LSE: London School of Economics and Political Science)H-Index: 12
30 CitationsSource
#1Tineke Kleinhout-Vliek (EUR: Erasmus University Rotterdam)H-Index: 1
#2Antoinette de Bont (EUR: Erasmus University Rotterdam)H-Index: 18
Last.Bert Boer (EUR: Erasmus University Rotterdam)H-Index: 2
view all 3 authors...
2 CitationsSource
5 CitationsSource
#1Padraig Dixon (UoB: University of Bristol)H-Index: 6
#2Charlotte Chamberlain (UoB: University of Bristol)H-Index: 6
Last.William HollingworthH-Index: 46
view all 3 authors...
5 CitationsSource
#1MeiLan K. Han (UM: University of Michigan)H-Index: 51
#2Carlos H. Martinez (UM: University of Michigan)H-Index: 14
Last.Mark T. Dransfield (UAB: University of Alabama at Birmingham)H-Index: 41
view all 28 authors...
24 CitationsSource